Latest Breaking News On - Neuromuscular disease - Page 4 : comparemela.com

UCB announces U S FDA approval of ZILBRYSQ® (zilucoplan) for the treatment of adults with generalized myasthenia gravis

UCB announces U S FDA approval of ZILBRYSQ® (zilucoplan) for the treatment of adults with generalized myasthenia gravis
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

Bruxelles capitaleAntje witteJim baxterJean christophe tellierDaphne teoIris loew friedrichSamantha mastersonHoward jf jrEculizumab solirisLaurent schotsMjamesf howardCorporate communicationsJapanese ministry of healthNational institute of neurological disordersGroup of companiesEuropean union

Gene Therapy Drugs Market Analysis and Future Prospects for 2030

Gene Therapy Drugs Market Analysis and Future Prospects for 2030

United statesAsia pacificParmeet singhDhirtek business researchNovartis internationalConsulting privateGilead sciences incGenetic technologies corpSample reportComprehensive analysisGene therapy drugsApplied genetic technologies corpAudentes therapeuticsBiomarin pharmaceuticalBluebird bioGilead sciences

PepGen (PEPG) Presents PGN-EDODM1 Preclinical Data

PepGen (PEPG) Presents PGN-EDODM1 Preclinical Data
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

District of columbiaUnited statesSarah suttonJames mcarthurLaurence wattsJaya goyalOttawa international conference on neuromuscular diseaseGilmartin groupResearch preclinical development at pepgenPepgen incMyotonic dystrophy foundationEnhanced delivery oligonucleotideOttawa international conferenceNeuromuscular diseaseDystrophy foundationAnnual conference

PepGen Inc Announces Clearance of CTA by Health Canada to Begin the FREEDOM-DM1 Phase 1 Study of PGN-EDODM1 in Patients with Myotonic Dystrophy Type 1

The U.S. Food and Drug Administration granted Orphan Drug Designation to PGN-EDODM1 for the treatment of Myotonic Dystrophy Type 1 BOSTON, Sept. 06, 2023 PepGen Inc. , a clinical-stage.

United statesJames mcarthurLaurence wattsSarah suttonHealth canadaPepgen incOttawa international conference on neuromuscular diseaseGilmartin groupMyotonic dystrophy foundationDrug administrationOrphan drug designationMyotonic dystrophy typeClinical trial applicationOrphan drug actOttawa international conferenceNeuromuscular disease

PepGen (PEPG) Announces Clearance of CTA by Health Canada to Begin the FREEDOM-DM1 Phase 1 Study of PGN-EDODM1

PepGen (PEPG) Announces Clearance of CTA by Health Canada to Begin the FREEDOM-DM1 Phase 1 Study of PGN-EDODM1
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesLaurence wattsSarah suttonJames mcarthurPepgen incHealth canadaDrug administrationGilmartin groupMyotonic dystrophy foundationOttawa international conference on neuromuscular diseaseClinical trial applicationOrphan drug actOttawa international conferenceNeuromuscular diseaseDystrophy foundationAnnual conference